EU/3/10/844

About

Please note that this product (marketed as Inlyta) was withdrawn from the Community Register of designated orphan medicinal products in July 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 23 February 2011, orphan designation (EU/3/10/844) was granted by the European Commission to Pfizer Limited, United Kingdom, for axitinib for the treatment of renal-cell carcinoma.

Key facts

Active substance
axitinib
Medicine name
Inlyta
Disease / condition
Treatment of renal-cell carcinoma
Date of first decision
23/02/2011
Outcome
Withdrawn
EU designation number
EU/3/10/844

Review of designation

Please note that this product (marketed as Inlyta) was withdrawn from the Community Register of designated orphan medicinal products in July 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Sandwich
Kent
CT13 0NJ
United Kingdom
Telephone: +44 13 04 61 61 61
Telefax: +44 13 04 65 62 21
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating